TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04167137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1891
Description: SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1891
Description: SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
Study: NCT04202133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW (formerly Weight Watchers)
Description: The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
Study: NCT00525096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets twice a day per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 2\*200 mg tablets twice a day per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg per day per os

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg per day per os
Study: NCT03265782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
Study: NCT01963156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription synchronization
Description: Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point.
Study: NCT03723746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-67670187
Description: Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
Study: NCT01849419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (MDMA)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (oxytocin)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (placebo)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
Study: NCT02283632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Diversion
Description: The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
Study: NCT01453608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject (ferric carboxymaltose)
Description: Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Subjects will receive Placebo (saline) intravenously on Day 0
Study: NCT01072253

Intervention type: PROCEDURE
Intervention: eye amputation
Study: NCT00306540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: oral flexible dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine fumarate placebo
Description: oral 0 mg
Study: NCT01199562

Intervention type: PROCEDURE
Intervention: infection prophylaxis and management
Description: Undergo infection prophylaxis and management

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Intervention: DNA analysis
Description: Correlative studies

Intervention type: GENETIC
Intervention: RNA analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: undergo infection prophylaxis and management
Study: NCT02009046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEI Classroom Curriculum
Description: Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Classroom Curriculum
Description: Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEI Curriculum + 3 School Components
Description: Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Curriculum + 1 School Component
Description: Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
Study: NCT00844272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education.
Study: NCT01909349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation
Description: Web-based support for behavior change regarding physical activity and fruit \& vegetable consumption
Study: NCT01199562

Intervention type: DRUG
Intervention: ganciclovir
Description: Given IV

Intervention type: DRUG
Intervention: valganciclovir
Description: Given orally

Intervention type: DRUG
Intervention: foscarnet sodium
Description: Given orally

Intervention type: PROCEDURE
Intervention: antiviral therapy
Description: undergo infection prophylaxis and management

Intervention type: GENETIC
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Intervention: protein expression analysis
Description: Correlative studies
Study: NCT03086486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets
Study: NCT02541734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusine
Description: Infusion of gelofusine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-exendin 4 SPECT/CT
Description: 111In-exendin 4 SPECT/CT

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 111In-exendin 4 SPECT/CT
Description: 111In-exendin 4 SPECT/CT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02268994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1 g ferric citrate containing approximately 210 mg of ferric iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01670773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-1004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate + DHA
Study: NCT04515550

Intervention type: DIAGNOSTIC_TEST
Intervention: lumbar puncture
Description: Some participants will have an optional lumbar puncture
Study: NCT01670773

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05266391

Intervention type: OTHER
Intervention: subacromial corticosteroid injections
Description: Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).

Intervention type: OTHER
Intervention: subacromial corticosteroid injections
Description: Patients with SAIS whose application of corticosteroid in their injections were the same in terms of type and dose (1 ml betamethasone dipropionate + betamethasone sodium phosphate).
Study: NCT04770792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate with mineral trioxide aggregate.
Description: 2% chlorhexidine gluconate with mineral trioxide aggregate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate.
Description: Mineral trioxide aggregate.
Study: NCT00267852

Intervention type: OTHER
Intervention: as clinical practice
Description: Dosage, form, frequency and duration as per ordinary clinical practice
Study: NCT02524418

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholangiopancreatoscopy
Description: An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
Study: NCT03665272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deepithelialized gingival graft fixation
Description: one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deepithelialized gingival graft fixation
Description: one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
Study: NCT03125772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Element™ Paclitaxel-Eluting Stent System
Description: Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience PRIME Everolimus-Eluting Stent System
Description: The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
Study: NCT02872272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Amikacin
Description: Aminoglycosides. Blood sampling for pharmacokinetic evaluation
Study: NCT04534270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks
Study: NCT03086486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets
Study: NCT02356692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enfilcon A
Description: Test lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Test lens
Study: NCT00980759

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EFI
Description: Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic RT
Description: Only Pelvic Irradiation with chemotherapy(cisplatin)
Study: NCT02037906

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Escalating Energy SWL
Description: Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Constant Energy SWL
Description: Constant dose at 20 kv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduction Energy SWL
Description: Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
Study: NCT03473899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: rESWT will be performed as follows:~* Nine rESWT sessions~* Three sessions per week~* rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~* 2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm\^2, depending on what the patient tolerates~* rESWs applied at 15 Hz~* Application of rESWs in prone position, with the patient lying on an examination table~* Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~* Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~* No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-rESWT
Description: Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program.
Study: NCT04316026

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shock wave therapy
Description: Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave therapy
Description: Shockwave therapy is a non-invasive treatment creating a series of low energy acoustic wave pulsations that are directly applied through the skin via a gel medium
Study: NCT03866564

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Cardiac ultrasound to measure left ventricular systolic function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Cardiac ultrasound to measure left ventricular systolic function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Cardiac ultrasound to measure left ventricular systolic function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Testing
Description: Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: Clinically accepted quantitative assessment of chronic pain burden.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: Clinically accepted quantitative assessment of chronic pain burden.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: Clinically accepted quantitative assessment of chronic pain burden.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal Polysomnography
Description: Routine overnight sleep study to measure apnea-hypopnea index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal Polysomnography
Description: Routine overnight sleep study to measure apnea-hypopnea index.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal Polysomnography
Description: Routine overnight sleep study to measure apnea-hypopnea index.
Study: NCT03086486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: Scored 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: Scored 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: Scored 600 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Linezolid
Description: Scored 600 mg tablets
Study: NCT04413110

Intervention type: DEVICE
Intervention: Polysomnography
Description: PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.

Intervention type: DEVICE
Intervention: Polysomnography
Description: PSG was carried out for 41 patients with subjective cognitive impairment and 41 age and sex-matched controls. PSG with standard EEG montage that includes bilateral EOG and four EEG leads were used. A single attended overnight PSG study was performed at the Clinical Neurophysiology Unit of Mansoura University Hospitals. Patients were studied in a quiet, darkened room with no medications were used to induce sleep. All participants underwent one night of laboratory-based PSG.
Study: NCT01807312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic CO2 regulation unit and accessories
Description: Olympus UCR Endoscopic CO2 Regulation Unit

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02233439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal galactagogue

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00611546

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photo-protection
Description: Parenteral solutions are protected from day light using aluminum covers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photo-exposure
Description: Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
Study: NCT02666729

Intervention type: PROCEDURE
Intervention: AF Ablation with contact force information
Description: Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.

Intervention type: PROCEDURE
Intervention: AF Ablation without contact force information
Description: Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.